SERB completes acquisition of BTG Specialty Pharmaceuticals
Time is her tissue image
Locate CroFab® > Watch Reconstitution Video > Use Treatment Algorithm >

CroFab® MEETS WORLD HEALTH ORGANIZATION (WHO) GUIDELINES FOR EFFECTIVE ANTIVENOM, UTILIZING VENOM FROM 4 CLINICALLY RELEVANT PIT VIPER SPECIES NATIVE TO REGIONS ACROSS THE UNITED STATES1,2

CroFab® is the only antivenom:

•Derived from geographically and clinically relevant US snakes for comprehensive coverage of all
North American pit viper envenomations1,2

•Designed with small, venom-specific protein (Fab) fragments for rapid neutralization of venom toxins
throughout affected tissue1,3

•With Level 1 evidence in the treatment of copperhead envenomation4

•Manufactured to yield the highest level of quality, purity, and safety1,5

•With a proven efficacy and safety profile, backed by >20 years of clinical experience1

•Reliably supplied throughout the United States5

 

Trust CroFab® >

INITIAL CONTROL FOR SNAKE ENVENOMATION INVOLVES
HALTING LOCAL, SYSTEMIC, AND HEMATOLOGIC EFFECTS1

Select an image to explore the effects.

Local effects

SYMPTOMS6

  • Swelling, tenderness, and pain
  • Redness
  • Ecchymosis
  • Bullae or blebs
  • Soft-tissue necrosis

CONSEQUENCES6-9

  • Partial or complete loss of affected limbs
  • Loss of joint functionality
  • Loss or impairment of tactile sensation
  • Infection
  • Cosmetic issues

Systemic effects

SYMPTOMS4

  • Hypotension
  • Bleeding beyond the puncture site
  • Refractory vomiting
  • Diarrhea
  • Angioedema
  • Neurotoxicity

CONSEQUENCES4,8

  • Death is a possibility
  • Irreversible damage
  • Respiratory compromise/failure
  • Neurologic deficits
  • Cardiovascular/pulmonary collapse due to shock
  • End organ damage

Hematologic effects

SYMPTOMS4

  • Decreased fibrinogen
  • Elevated prothrombin time or international normalized ratio
  • Thrombocytopenia

CONSEQUENCES4,8

  • Coagulation abnormalities
  • Increased risk of bleeding complications (0.5%)
  • Significant ecchymosis
  • Anemia

Crofab® Patient Testimonials

▶

Caitlyn

▶

Daniel

▶

Jessica

▶

Julia and Laura

▶

Julie and Haley

PREPARE TO STRIKE BACK AGAINST PIT VIPER ENVENOMATION

Triple Control

Gain triple control with CroFab®*

CroFab® is proven to halt local effects, resolve systemic effects, and reduce coagulation abnormalities.1,10

LEARN MORE >
Treatment Algorithm

How to treat a snakebite

Use the interactive guide with step-by-step instructions on how to treat a snakebite.

TREAT NOW > LEARN MORE >
Dosing and Administration

Dosing and administration

Dose CroFab® appropriately to gain and continue control of envenomation.1,6

LEARN MORE >

How to Order CroFab®

Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care11

• All hospitals that provide emergency care should stock 12 to 18 vials of CroFab®—enough antidote to treat
one patient for 8 to 24 hours

Learn how to order CroFab® >

*Efficacy determined using the snakebite severity score (SSS), a validated objective tool for the clinical evaluation of North American pit viper snakebite in adults. The total score reflects patient evaluation on 6 dimensions: cardiovascular system, local wound, gastrointestinal system, hematologic symptoms, pulmonary system, and central nervous system. The higher the total score, the more severe the snakebite.1


References:

1. CroFab® [prescribing Information]. BTG International Inc; January 2018. 2. WHO Expert Committee on Biological Standardization. Guidelines for the production, control and regulation of snake antivenom immunoglobulins. Geneva, Switzerland: World Health Organization. WHO Technical Report Series, No. 1004, Annex 5. 2017. 3. Laustsen AH, María Gutiérrez J, Knudsen C, et al. Pros and cons of different therapeutic antibody formats for recombinant antivenom development. Toxicon. 2018;146:151-175. 4. Gerardo CJ, Quackenbush E, Lewis B, et al. The efficacy of Crotalidae polyvalent immune Fab (ovine) antivenom versus placebo plus optional rescue therapy on recovery from copperhead snake envenomation: a randomized, double-blind, placebo-controlled, clinical trial. Ann Emerg Med. 2017;70(2):233-244. 5. Data on file. Conshohocken, PA; BTG International Inc. 2019. 6. Lavonas EJ, Ruha AM, Banner W, et al. Unified treatment algorithm for the management of crotaline snakebite in the United States: results of an evidence-informed consensus workshop. BMC Emerg Med. 2011;11:2. 7. Nelson L, Lewin N, Howland M, et al. Goldfrank’s Toxicologic Emergencies. 9th ed. McGraw Hill Medical; 2010:1601-1609. 8. Ruha AM, Kleinschmidt KC, Greene S, et al. The epidemiology, clinical course, and management of snakebites in the North American Snakebite Registry. J Med Toxicol. 2017;13(4):309-320. 9. Mackessy SP, ed. Handbook of Venoms and Toxins of Reptiles. Boca Raton, FL: CRC Press; 2010. 10. Dart RC, Seifert SA, Boyer LV, et al. A randomized multicenter trial of crotalinae polyvalent immune Fab (ovine) antivenom for the treatment for crotaline snakebite in the United States. Arch Intern Med. 2001;161(16):2030-2036. 11. Dart RC, Goldfrank LR, Erstad BL, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. Ann Emerg Med. 2018;71(3):314-325.